Tenova Pharmaceuticals  |  SKU: T71117-1mg

Azide-Hexanoyl-Val-Cit-PAB(m-PEG8)-MMAE

Regular price $490.00
Size

SOLU-KNEX® cleavable linker features a Val-Cit dipeptide. m-PEG8 is attached to the commonly used self-immolative para-aminobenzyl (PAB) moiety to increase aqueous solubility. The payload is monomethyl auristatin E (MMAE), a highly potent antimitotic agent that inhibits tubulin polymerization, leading to cell-cycle arrest and subsequent apoptosis.

Derived from established ADC linker architectures, SOLU-KNEX® ADC linkers integrate solubilizing moieties—such as PEG, amine-containing groups, or polysarcosine (PSAR), to enhance aqueous solubility. Solubility and physicochemical properties can be finely tuned through selection and combination of these groups, making the linkers highly adaptable for diverse ADC and related applications. SOLU-KNEX® is a registered trademark of Tenova Pharmaceuticals, Inc. For research use only.

Product Name Azide-Hexanoyl-Val-Cit-PAB(m-PEG8)-MMAE
Synonyms
CAS Number
Related CAS
Molecular Formula C82H138N14O22
Molecular Weight 1672.082
Purity (HPLC) >= 95%
Solubility DMSO, DMF
Shipping Conditions Shipped on gel packs
Storage Conditions Store at -20°C and protected from light
Shelf Life 12 months after the date of delivery
Regulatory Statement For Research Use Only


References

(1) Yamazoe, S., Poudel, Y., Sega, E., Mukhopadhyay, A., Ramakrishnan, R., Ukairo, O., Liu, S., Akter, R., Sadanala, K., Que, K., Cheng, Q., Kotapati, S., Deshpande, M., Cox, M., Chourey, S., Gupta, A., Kempson, J., Pabbisetty, K., Kaspady, M., … Chekler, E. P. (2025). Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00355

 

Documents 

Datasheet          MSDS

 

Citations

If you know of a paper that uses this product from Tenova Pharma, please let us know.